Open Access

Benefits of using probiotics as adjuvants in anticancer therapy (Review)

  • Authors:
    • Silvia Vivarelli
    • Luca Falzone
    • Maria Sofia Basile
    • Daria Nicolosi
    • Carlo Genovese
    • Massimo Libra
    • Mario Salmeri
  • View Affiliations

  • Published online on: June 3, 2019     https://doi.org/10.3892/wasj.2019.13
  • Pages: 125-135
  • Copyright: © Vivarelli et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer is the second leading cause of mortality worldwide and the constant search for novel therapeutics aims to increase the overall survival of the affected population. The human microbiota evolves with the host throughout the course of its entire life, as a direct consequence of individual diet and lifestyle habits. The gut microbiota tremendously affects human homeostasis and it has been widely observed that maintaining a healthy gut may prevent diseases, as well as ameliorate pathological conditions. According to the World Health Organization, probiotics may confer a health benefit on the host when administered in adequate amounts. Anticancer therapy often causes severe side‑effects, including gastrointestinal toxicity. Several clinical trials have highlighted the efficacy of administering probiotics to cancer patients receiving anticancer care, with proven efficacy in reducing gut‑related and life‑threatening side‑effects. To corroborate the clinical results, recent translational studies have indicated that the specific administration of selected bacterial gut species are capable of improving the immune check‑point immunotherapy clinical outcome. Lactobacillus rhamnosus GG (LGG), a model probiotic widely studied in oncology, has been proven to be beneficial when administered during anticancer therapy. In this review, we report the up‑to‑date clinical advancements obtained following the administration of probiotics during anticancer therapy, with particular focus on the promising probiotic strain LGG.

References

1 

Ursell LK, Metcalf JL, Parfrey LW and Knight R: Defining the human microbiome. Nutr Rev. 70 (Suppl 1):S38–S44. 2012.PubMed/NCBI View Article : Google Scholar

2 

Zhang YJ, Li S, Gan RY, Zhou T, Xu DP and Li HB: Impacts of gut bacteria on human health and diseases. Int J Mol Sci. 16:7493–7519. 2015.PubMed/NCBI View Article : Google Scholar

3 

Feng Q, Chen WD and Wang YD: Gut Microbiota: An Integral Moderator in Health and Disease. Front Microbiol. 9(151)2018.PubMed/NCBI View Article : Google Scholar

4 

Lynch SV and Pedersen O: The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 375:2369–2379. 2016.PubMed/NCBI View Article : Google Scholar

5 

Greenhalgh K, Meyer KM, Aagaard KM and Wilmes P: The human gut microbiome in health: Establishment and resilience of microbiota over a lifetime. Environ Microbiol. 18:2103–2116. 2016.PubMed/NCBI View Article : Google Scholar

6 

Neuman H, Debelius JW, Knight R and Koren O: Microbial endocrinology: The interplay between the microbiota and the endocrine system. FEMS Microbiol Rev. 39:509–521. 2015.PubMed/NCBI View Article : Google Scholar

7 

Ceranowicz P, Warzecha Z and Dembinski A: Peptidyl hormones of endocrine cells origin in the gut--their discovery and physiological relevance. J Physiol Pharmacol. 66:11–27. 2015.PubMed/NCBI

8 

Sandrini S, Aldriwesh M, Alruways M and Freestone P: Microbial endocrinology: Host-bacteria communication within the gut microbiome. J Endocrinol. 225:R21–R34. 2015.PubMed/NCBI View Article : Google Scholar

9 

Ravussin Y, Koren O, Spor A, LeDuc C, Gutman R, Stombaugh J, Knight R, Ley RE and Leibel RL: Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity (Silver Spring). 20:738–747. 2012.PubMed/NCBI View Article : Google Scholar

10 

Queipo-Ortuño MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, Casanueva F and Tinahones FJ: Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. PLoS One. 8(e65465)2013.PubMed/NCBI View Article : Google Scholar

11 

Gensollen T, Iyer SS, Kasper DL and Blumberg RS: How colonization by microbiota in early life shapes the immune system. Science. 352:539–544. 2016.PubMed/NCBI View Article : Google Scholar

12 

Schmidt TSB, Raes J and Bork P: The Human Gut Microbiome: From Association to Modulation. Cell. 172:1198–1215. 2018.PubMed/NCBI View Article : Google Scholar

13 

Bultman SJ: Emerging roles of the microbiome in cancer. Carcinogenesis. 35:249–255. 2014.PubMed/NCBI View Article : Google Scholar

14 

Cani PD: Human gut microbiome: Hopes, threats and promises. Gut. 67:1716–1725. 2018.PubMed/NCBI View Article : Google Scholar

15 

Mohajeri MH, Brummer RJM, Rastall RA, Weersma RK, Harmsen HJM, Faas M and Eggersdorfer M: The role of the microbiome for human health: From basic science to clinical applications. Eur J Nutr. 57 (Suppl 1):1–14. 2018.PubMed/NCBI View Article : Google Scholar

16 

Fukui H, Xu X and Miwa H: Role of Gut Microbiota-Gut Hormone Axis in the Pathophysiology of Functional Gastrointestinal Disorders. J Neurogastroenterol Motil. 24:367–386. 2018.PubMed/NCBI View Article : Google Scholar

17 

Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF and Dinan TG: Minireview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol. 28:1221–1238. 2014.PubMed/NCBI View Article : Google Scholar

18 

Vaishnava S, Behrendt CL, Ismail AS, Eckmann L and Hooper LV: Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA. 105:20858–20863. 2008.PubMed/NCBI View Article : Google Scholar

19 

Belkaid Y and Naik S: Compartmentalized and systemic control of tissue immunity by commensals. Nat Immunol. 14:646–653. 2013.PubMed/NCBI View Article : Google Scholar

20 

Magnúsdóttir S, Ravcheev D, de Crécy-Lagard V and Thiele I: Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. Front Genet. 6(148)2015.PubMed/NCBI View Article : Google Scholar

21 

Carding S, Verbeke K, Vipond DT, Corfe BM and Owen LJ: Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 26(26191)2015.PubMed/NCBI View Article : Google Scholar

22 

Grice EA and Segre JA: The human microbiome: Our second genome. Annu Rev Genomics Hum Genet. 13:151–170. 2012.PubMed/NCBI View Article : Google Scholar

23 

Geva-Zatorsky N, Sefik E, Kua L, Pasman L, Tan TG Ortiz-Lopez A, Yanortsang TB, Yang L, Jupp R, Mathis D, et al: Mining the Human Gut Microbiota for Immunomodulatory Organisms. Cell. 168:928–943.e11. 2017.PubMed/NCBI View Article : Google Scholar

24 

Haber AL, Biton M, Rogel N, Herbst RH, Shekhar K, Smillie C, Burgin G, Delorey TM, Howitt MR, Katz Y, et al: A single-cell survey of the small intestinal epithelium. Nature. 551:333–339. 2017.PubMed/NCBI View Article : Google Scholar

25 

Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC, Stewart CJ, Metcalf GA, Muzny DM, Gibbs RA, et al: The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome. 5(153)2017.PubMed/NCBI View Article : Google Scholar

26 

Lloyd-Price J, Mahurkar A, Rahnavard G, Crabtree J, Orvis J, Hall AB, Brady A, Creasy HH, McCracken C, Giglio MG, et al: Strains, functions and dynamics in the expanded Human Microbiome Project. Nature. 550:61–66. 2017.PubMed/NCBI View Article : Google Scholar

27 

Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN, Bar N, et al: Environment dominates over host genetics in shaping human gut microbiota. Nature. 555:210–215. 2018.PubMed/NCBI View Article : Google Scholar

28 

Korem T, Zeevi D, Suez J, Weinberger A, Avnit-Sagi T, Pompan-Lotan M, Matot E, Jona G, Harmelin A, Cohen N, et al: Growth dynamics of gut microbiota in health and disease inferred from single metagenomic samples. Science. 349:1101–1106. 2015.PubMed/NCBI View Article : Google Scholar

29 

Lloyd-Price J, Abu-Ali G and Huttenhower C: The healthy human microbiome. Genome Med. 8(51)2016.PubMed/NCBI View Article : Google Scholar

30 

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al: Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 11:506–514. 2014.PubMed/NCBI View Article : Google Scholar

31 

Pandey KR, Naik SR and Vakil BV: Probiotics, prebiotics and synbiotics- a review. J Food Sci Technol. 52:7577–7587. 2015.PubMed/NCBI View Article : Google Scholar

32 

Tsai YL, Lin TL, Chang CJ, Wu TR, Lai WF, Lu CC and Lai HC: Probiotics, prebiotics and amelioration of diseases. J Biomed Sci. 26(3)2019.PubMed/NCBI View Article : Google Scholar

33 

Goodman B and Gardner H: The microbiome and cancer. J Pathol. 244:667–676. 2018.PubMed/NCBI View Article : Google Scholar

34 

Tomasetti C and Vogelstein B: Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 347:78–81. 2015.PubMed/NCBI View Article : Google Scholar

35 

Ashford NA, Bauman P, Brown HS, Clapp RW, Finkel AM, Gee D, Hattis DB, Martuzzi M, Sasco AJ and Sass JB: Cancer risk: Role of environment. Science. 347(727)2015.PubMed/NCBI View Article : Google Scholar

36 

Polo A, Crispo A, Cerino P, Falzone L, Candido S, Giudice A, De Petro G, Ciliberto G, Montella M, Budillon A, et al: Environment and bladder cancer: Molecular analysis by interaction networks. Oncotarget. 8:65240–65252. 2017.PubMed/NCBI View Article : Google Scholar

37 

Falzone L, Marconi A, Loreto C, Franco S, Spandidos DA and Libra M: Occupational exposure to carcinogens: Benzene, pesticides and fibers (Review). Mol Med Rep. 14:4467–4474. 2016.PubMed/NCBI View Article : Google Scholar

38 

Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B and Aggarwal BB: Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 25:2097–2116. 2008.PubMed/NCBI View Article : Google Scholar

39 

Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al: Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 3:524–548. 2017.PubMed/NCBI View Article : Google Scholar

40 

Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, Casey DC, Charlson FJ, Chen AZ, Coates MM, et al: GBD 2015 Mortality and Causes of Death Collaborators: Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 388:1459–1544. 2016.PubMed/NCBI View Article : Google Scholar

41 

Rapisarda V, Salemi R, Marconi A, Loreto C, Graziano AC, Cardile V, Basile MS, Candido S, Falzone L, Spandidos DA, et al: Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells. Oncol Lett. 12:3363–3367. 2016.PubMed/NCBI View Article : Google Scholar

42 

Rapisarda V, Ledda C, Matera S, Fago L, Arrabito G, Falzone L, Marconi A, Libra M and Loreto C: Absence of t(14;18) chromosome translocation in agricultural workers after short-term exposure to pesticides. Mol Med Rep. 15:3379–3382. 2017.PubMed/NCBI View Article : Google Scholar

43 

Fenga C, Gangemi S, Di Salvatore V, Falzone L and Libra M: Immunological effects of occupational exposure to lead (Review). Mol Med Rep. 15:3355–3360. 2017.PubMed/NCBI View Article : Google Scholar

44 

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science. 339:1546–1558. 2013.PubMed/NCBI View Article : Google Scholar

45 

Guarneri C, Bevelacqua V, Polesel J, Falzone L, Cannavò PS, Spandidos DA, Malaponte G and Libra M: NF-κB inhibition is associated with OPN/MMP-9 downregulation in cutaneous melanoma. Oncol Rep. 37:737–746. 2017.PubMed/NCBI View Article : Google Scholar

46 

Salemi R, Falzone L, Madonna G, Polesel J, Cinà D, Mallardo D, Ascierto PA, Libra M and Candido S: MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA. Front Pharmacol. 9(856)2018.PubMed/NCBI View Article : Google Scholar

47 

Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, Candido S and Libra M: Cutaneous melanoma: From pathogenesis to therapy (Review). Int J Oncol. 52:1071–1080. 2018.PubMed/NCBI View Article : Google Scholar

48 

Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, et al: Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med. 21:440–448. 2015.PubMed/NCBI View Article : Google Scholar

49 

Kloor M and von Knebel Doeberitz M: The Immune Biology of Microsatellite-Unstable Cancer. Trends Cancer. 2:121–133. 2016.PubMed/NCBI View Article : Google Scholar

50 

Carter SL, Eklund AC, Kohane IS, Harris LN and Szallasi Z: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 38:1043–1048. 2006.PubMed/NCBI View Article : Google Scholar

51 

Dagogo-Jack I and Shaw AT: Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 15:81–94. 2018.PubMed/NCBI View Article : Google Scholar

52 

Falzone L, Romano GL, Salemi R, Bucolo C, Tomasello B, Lupo G, Anfuso CD, Spandidos DA, Libra M and Candido S: Prognostic significance of deregulated microRNAs in uveal melanomas. Mol Med Rep. 19:2599–2610. 2019.PubMed/NCBI View Article : Google Scholar

53 

Battaglia R, Palini S, Vento ME, La Ferlita A, Lo Faro MJ, Caroppo E, Borzì P, Falzone L, Barbagallo D, Ragusa M, et al: Identification of extracellular vesicles and characterization of miRNA expression profiles in human blastocoel fluid. Sci Rep. 9(84)2019.PubMed/NCBI View Article : Google Scholar

54 

Basile MS, Fagone P, Mangano K, Mammana S, Magro G, Salvatorelli L, Li Destri G, La Greca G, Nicoletti F, Puleo S and Pesce A: KCNMA1 Expression is Downregulated in Colorectal Cancer via Epigenetic Mechanisms. Cancers (Basel). 11pii. (E245)2019.PubMed/NCBI View Article : Google Scholar

55 

Falzone L, Scola L, Zanghì A, Biondi A, Di Cataldo A, Libra M and Candido S: Integrated analysis of colorectal cancer microRNA datasets: Identification of microRNAs associated with tumor development. Aging (Albany NY). 10:1000–1014. 2018.PubMed/NCBI View Article : Google Scholar

56 

McCubrey JA, Fitzgerald TL, Yang LV, Lertpiriyapong K, Steelman LS, Abrams SL, Montalto G, Cervello M, Neri LM, Cocco L, et al: Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget. 8:14221–14250. 2017.PubMed/NCBI View Article : Google Scholar

57 

Falzone L, Candido S, Salemi R, Basile MS, Scalisi A, McCubrey JA, Torino F, Signorelli SS, Montella M and Libra M: Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. Oncotarget. 7:72758–72766. 2016.PubMed/NCBI View Article : Google Scholar

58 

Hafsi S, Candido S, Maestro R, Falzone L, Soua Z, Bonavida B, Spandidos DA and Libra M: Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. Oncol Lett. 11:1021–1025. 2016.PubMed/NCBI View Article : Google Scholar

59 

Falzone L, Lupo G, Rosa GRM, Crimi S, Anfuso CD, Salemi R, Rapisarda E, Libra M and Candido S: Identification of Novel MicroRNAs and Their Diagnostic and Prognostic Significance in Oral Cancer. Cancers (Basel). 11pii. (E610)2019.PubMed/NCBI View Article : Google Scholar

60 

Falzone L, Salemi R, Travali S, Scalisi A, McCubrey JA, Candido S and Libra M: MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. Aging (Albany NY). 8:933–944. 2016.PubMed/NCBI View Article : Google Scholar

61 

Dy GK and Adjei AA: Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 63:249–279. 2013.PubMed/NCBI View Article : Google Scholar

62 

McGranahan N and Swanton C: Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 27:15–26. 2015.PubMed/NCBI View Article : Google Scholar

63 

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al: Cancer Genome Atlas Research Network: The Immune Landscape of Cancer. Immunity. 48:812–830.e14. 2018.PubMed/NCBI View Article : Google Scholar

64 

Presti M, Mazzon E, Basile MS, Petralia MC, Bramanti A, Colletti G, Bramanti P, Nicoletti F and Fagone P: Overexpression of macrophage migration inhibitory factor and functionally-related genes, D-DT, CD74, CD44, CXCR2 and CXCR4, in glioblastoma. Oncol Lett. 16:2881–2886. 2018.PubMed/NCBI View Article : Google Scholar

65 

Mangano K, Mazzon E, Basile MS, Di Marco R, Bramanti P, Mammana S, Petralia MC, Fagone P and Nicoletti F: Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. Oncotarget. 9:17951–17970. 2018.PubMed/NCBI View Article : Google Scholar

66 

Basile MS, Mazzon E, Russo A, Mammana S, Longo A, Bonfiglio V, Fallico M, Caltabiano R, Fagone P, Nicoletti F, et al: Differential modulation and prognostic values of immune-escape genes in uveal melanoma. PLoS One. 14(e0210276)2019.PubMed/NCBI View Article : Google Scholar

67 

Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B and Marincola FM: Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 81:116–129. 2017.PubMed/NCBI View Article : Google Scholar

68 

Toh HC: Cancer immunotherapy-the end of the beginning. Linchuang Zhongliuxue Zazhi. 7(12)2018.PubMed/NCBI View Article : Google Scholar

69 

Roy S and Trinchieri G: Microbiota: A key orchestrator of cancer therapy. Nat Rev Cancer. 17:271–285. 2017.PubMed/NCBI View Article : Google Scholar

70 

Nayak RR and Turnbaugh PJ: Mirror, mirror on the wall: Which microbiomes will help heal them all? BMC Med. 14(72)2016.PubMed/NCBI View Article : Google Scholar

71 

Fessler JL and Gajewski TF: The Microbiota: A New Variable Impacting Cancer Treatment Outcomes. Clin Cancer Res. 23:3229–3231. 2017.PubMed/NCBI View Article : Google Scholar

72 

Schwabe RF and Jobin C: The microbiome and cancer. Nat Rev Cancer. 13:800–812. 2013.PubMed/NCBI View Article : Google Scholar

73 

Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A and Wargo JA: The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell. 33:570–580. 2018.PubMed/NCBI View Article : Google Scholar

74 

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 359:91–97. 2018.PubMed/NCBI View Article : Google Scholar

75 

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 359:97–103. 2018.PubMed/NCBI View Article : Google Scholar

76 

Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ and Gajewski TF: The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 359:104–108. 2018.PubMed/NCBI View Article : Google Scholar

77 

Chen Q, Wang C, Chen G, Hu Q and Gu Z: Delivery Strategies for Immune Checkpoint Blockade. Adv Healthc Mater. 7(e1800424)2018.PubMed/NCBI View Article : Google Scholar

78 

Buchbinder EI and Desai A: CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 39:98–106. 2016.PubMed/NCBI View Article : Google Scholar

79 

Falzone L, Salomone S and Libra M: Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 9(1300)2018.PubMed/NCBI View Article : Google Scholar

80 

Mego M, Holec V, Drgona L, Hainova K, Ciernikova S and Zajac V: Probiotic bacteria in cancer patients undergoing chemotherapy and radiation therapy. Complement Ther Med. 21:712–723. 2013.PubMed/NCBI View Article : Google Scholar

81 

Maria-Aggeliki KS, Nikolaos KL, Kyrias GM and Vassilis KE: The potential clinical impact of probiotic treatment for the prevention and/or anti-inflammatory therapeutic effect against radiation induced intestinal mucositis. A review. Recent Pat Inflamm Allergy Drug Discov. 3:195–200. 2009. View Article : Google Scholar

82 

Rondanelli M, Faliva MA, Perna S, Giacosa A, Peroni G and Castellazzi AM: Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses. Gut Microbes. 8:521–543. 2017.PubMed/NCBI View Article : Google Scholar

83 

Zitvogel L, Ma Y, Raoult D, Kroemer G and Gajewski TF: The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 359:1366–1370. 2018.PubMed/NCBI View Article : Google Scholar

84 

Vanderhoof JA and Young R: Probiotics in the United States. Clin Infect Dis. 46 (Suppl 2):S67–S72; discussion S144-S151. 2008.PubMed/NCBI View Article : Google Scholar

85 

Redman MG, Ward EJ and Phillips RS: The efficacy and safety of probiotics in people with cancer: A systematic review. Ann Oncol. 25:1919–1929. 2014.PubMed/NCBI View Article : Google Scholar

86 

Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J and Committee EG: ESMO Guidelines Committee Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 26 (Suppl 5):v139–v151. 2015. View Article : Google Scholar

87 

Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, et al: Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO): MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 120:1453–1461. 2014.PubMed/NCBI View Article : Google Scholar

88 

Gianotti L, Morelli L, Galbiati F, Rocchetti S, Coppola S, Beneduce A, Gilardini C, Zonenschain D, Nespoli A and Braga M: A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol. 16:167–175. 2010.PubMed/NCBI View Article : Google Scholar

89 

Demers M, Dagnault A and Desjardins J: A randomized double-blind controlled trial: Impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr. 33:761–767. 2014.PubMed/NCBI View Article : Google Scholar

90 

Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B, Beniak J, Medvecova L, et al: Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement Ther Med. 23:356–362. 2015.PubMed/NCBI View Article : Google Scholar

91 

Theodoropoulos GE, Memos NA, Peitsidou K, Karantanos T, Spyropoulos BG and Zografos G: Synbiotics and gastrointestinal function-related quality of life after elective colorectal cancer resection. Ann Gastroenterol. 29:56–62. 2016.PubMed/NCBI

92 

Consoli ML, da Silva RS, Nicoli JR, Bruña-Romero O, da Silva RG, de Vasconcelos Generoso S and Correia MI: Randomized Clinical Trial: Impact of Oral Administration of Saccharomyces boulardii on Gene Expression of Intestinal Cytokines in Patients Undergoing Colon Resection. JPEN J Parenter Enteral Nutr. 40:1114–1121. 2016.PubMed/NCBI View Article : Google Scholar

93 

Flesch AT, Tonial ST, Contu PC and Damin DC: Perioperative synbiotics administration decreases postoperative infections in patients with colorectal cancer: A randomized, double-blind clinical trial. Rev Col Bras Cir. 44:567–573. 2017.PubMed/NCBI View Article : Google Scholar

94 

Goldin BR, Gualtieri LJ and Moore RP: The effect of Lactobacillus GG on the initiation and promotion of DMH-induced intestinal tumors in the rat. Nutr Cancer. 25:197–204. 1996.PubMed/NCBI View Article : Google Scholar

95 

Banna GL, Torino F, Marletta F, Santagati M, Salemi R, Cannarozzo E, Falzone L, Ferraù F and Libra M: Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer. Front Pharmacol. 8(603)2017.PubMed/NCBI View Article : Google Scholar

96 

Lee CS, Ryan EJ and Doherty GA: Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation. World J Gastroenterol. 20:3751–3761. 2014.PubMed/NCBI View Article : Google Scholar

97 

Khailova L, Baird CH, Rush AA, Barnes C and Wischmeyer PE: Lactobacillus rhamnosus GG treatment improves intestinal permeability and modulates inflammatory response and homeostasis of spleen and colon in experimental model of Pseudomonas aeruginosa pneumonia. Clin Nutr. 36:1549–1557. 2017.PubMed/NCBI View Article : Google Scholar

98 

Wang Y, Liu L, Moore DJ, Shen X, Peek RM, Acra SA, Li H, Ren X, Polk DB and Yan F: An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells. Mucosal Immunol. 10:373–384. 2017.PubMed/NCBI View Article : Google Scholar

99 

Fong FLY, Kirjavainen PV and El-Nezami H: Immunomodulation of Lactobacillus rhamnosus GG (LGG)-derived soluble factors on antigen-presenting cells of healthy blood donors. Sci Rep. 6(22845)2016.PubMed/NCBI View Article : Google Scholar

100 

Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, Torino F, Banna GL, Tonini G and Libra M: Gut Microbiota and Cancer: From Pathogenesis to Therapy. Cancers (Basel). 11pii. (E38)2019.PubMed/NCBI View Article : Google Scholar

101 

Riehl TE, Alvarado D, Ee X, Zuckerman A, Foster L, Kapoor V, Thotala D, Ciorba MA and Stenson WF: GG protects the intestinal epithelium from radiation injury through release of lipoteichoic acid, macrophage activation and the migration of mesenchymal stem cells. Gut. 68:1003–1013. 2018.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

May 2019
Volume 1 Issue 3

Print ISSN: 2632-2900
Online ISSN:2632-2919

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Vivarelli, S., Falzone, L., Basile, M.S., Nicolosi, D., Genovese, C., Libra, M., & Salmeri, M. (2019). Benefits of using probiotics as adjuvants in anticancer therapy (Review). World Academy of Sciences Journal, 1, 125-135. https://doi.org/10.3892/wasj.2019.13
MLA
Vivarelli, S., Falzone, L., Basile, M. S., Nicolosi, D., Genovese, C., Libra, M., Salmeri, M."Benefits of using probiotics as adjuvants in anticancer therapy (Review)". World Academy of Sciences Journal 1.3 (2019): 125-135.
Chicago
Vivarelli, S., Falzone, L., Basile, M. S., Nicolosi, D., Genovese, C., Libra, M., Salmeri, M."Benefits of using probiotics as adjuvants in anticancer therapy (Review)". World Academy of Sciences Journal 1, no. 3 (2019): 125-135. https://doi.org/10.3892/wasj.2019.13